You just read:

Avillion Announces Completion of Enrolment in Phase III BFORE Trial to Assess BOSULIF® (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia

News provided by

Avillion LLP

Sep 15, 2015, 04:00 ET